Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors
NCT06573294 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this trial is to study the antibody GEN1057 when used as a single agent for the treatment of certain types of cancer. Trial details include: * The trial duration for an individual participant will be up to approximately 11 months. * The treatment duration for an individual participant will be up to approximately 4 months (the duration of treatment may vary for each participant) and the follow-up duration for an individual participant will be approximately 6 months. Participation in the trial will require visits to the site. All participants will receive active drug; no one will be given placebo.
Conditions Studied
Interventions
- DRUG GEN1057
- DRUG Premedication
Study Locations (5)
Other
- National Cancer Center, Tsukiji 5-1-1 — Tokyo
- Start Madrid Centro Integral Oncologico Clara Campal CIOCC — Madrid
Tennessee
- SCRI Oncology Partners — Nashville
Texas
- South Texas Accelerated Research Therapeutics, LLC — San Antonio
Barcelona
- Hospital Universitari Vall d'Hebron — Barcelona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-08-28 |
| Est. Completion | 2027-09-21 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06573294
The ClinicalTrials.gov registry entry for NCT06573294 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genmab, which has 59 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Advanced Malignant Solid Tumors appearing as the primary indexed condition, and to 2 interventions — of which GEN1057 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06573294 reports 5 study locations spanning 4 distinct geographic areas — top geographies include Other, Tennessee, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06573294 about?
NCT06573294 is a clinical study titled "Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors". The purpose of this trial is to study the antibody GEN1057 when used as a single agent for the treatment of certain types of cancer. Trial details include: * The trial duration for an individual participant will be up to approximately 11 months. * The treatment duration for an individual participa...
What is the current status of trial NCT06573294?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2024-08-28. Estimated completion is 2027-09-21.
What conditions does trial NCT06573294 study?
This clinical trial studies the following conditions: Advanced Malignant Solid Tumors, Metastatic Malignant Solid Tumors. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06573294?
The interventions under investigation include: GEN1057 (DRUG), Premedication (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06573294?
This trial is sponsored by Genmab, which has 59 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06573294 being conducted?
This trial has 5 study locations across Tennessee, Texas, Barcelona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.